ASH 2024 Summary: Myeloma Highlights and Impact on Practice

2024 ASH Annual Meeting Insights Hub

H. Hashmi

ASH 2024 Review: Key Multiple Myeloma Abstracts

Cleveland Clinic Taussig Cancer Institute

N. Callander

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

Overview of Monoclonal Gammopathies From MGUS to Smoldering Myeloma

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

M. Kwok

Managing Amyloidosis in 2024: Diagnosis and Treatment

Indy Hematology Review

M. Gertz

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Management of AL Amyloidosis

GRACE

S. Rajeeve

Experts Discuss the Management of Monoclonal Gammopathy of Renal Sig…

MyCancerHaven

R. Vij, N. Leung

ASH 2025 Review: Advances in High-Risk SMM - Perspectives for Practi…

University of Colorado Division of Hematology

J. Monge

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGUS Fro…

Insights from 2023 ASH Annual Meeting

R. Banerjee

POEMS Syndrome Management

MyCancerHaven

R. Vij, D. Dingli

ASH 2024 Insights: Ph3 ANDROMEDA - Subcutaneous Dara + VCd in Newly …

2024 ASH Annual Meeting Insights Hub

E. Kastritis

Should Patients With High-Risk SMM Be Treated Outside a Clinical Tri…

Scripps Health

M. Gertz

Updates on AL Amyloidosis Treatment: What’s New in 2024

Dana-Farber Cancer Institute

G. Bianchi

ASH 2024 Insights: Cilta-Cel CAR-T in High-Risk SMM - Results From C…

2024 ASH Annual Meeting Insights Hub

O. Nadeem

Smoldering Myeloma: If and When to Treat

Victor Jimenez Zepeda

Approaches to Risk Stratification in Smoldering Myeloma

ecancer

I. Ghobrial

Chapter 2: Unmet Needs in Amyloidosis Diagnosis and Care - Vaishali …

Springer Healthcare IME

V. Sanchorawala

Diagnosing AL Amyloidosis

GRACE

S. Rajeeve

Treatment Approach for High-Risk Smoldering Myeloma

GRACE

M. Stanchina, S. Rajeeve, H. Hashmi